- Home
- NRO vs PROK Comparison
NRO vs PROK Comparison
Compare NRO & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- PROK
- Stock Information
- Founded
- NRO 2003
- PROK 2015
- Country
- NRO United States
- PROK United States
- Employees
- NRO N/A
- PROK 163
- Industry
- NRO Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRO Finance
- PROK Health Care
- Exchange
- NRO Nasdaq
- PROK Nasdaq
- Market Cap
- NRO 187.8M
- PROK 212.4M
- IPO Year
- NRO N/A
- PROK N/A
- Fundamental
- Price
- NRO $3.59
- PROK $1.66
- Analyst Decision
- NRO
- PROK Buy
- Analyst Count
- NRO 0
- PROK 5
- Target Price
- NRO N/A
- PROK $4.50
- AVG Volume (30 Days)
- NRO 239.4K
- PROK 566.3K
- Earning Date
- NRO 01-01-0001
- PROK 11-12-2024
- Dividend Yield
- NRO 11.41%
- PROK N/A
- EPS Growth
- NRO N/A
- PROK N/A
- EPS
- NRO N/A
- PROK N/A
- Revenue
- NRO N/A
- PROK N/A
- Revenue This Year
- NRO N/A
- PROK N/A
- Revenue Next Year
- NRO N/A
- PROK N/A
- P/E Ratio
- NRO N/A
- PROK N/A
- Revenue Growth
- NRO N/A
- PROK N/A
- 52 Week Low
- NRO $2.51
- PROK $1.18
- 52 Week High
- NRO $3.45
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- NRO 50.96
- PROK 46.29
- Support Level
- NRO $3.45
- PROK $1.50
- Resistance Level
- NRO $3.64
- PROK $1.90
- Average True Range (ATR)
- NRO 0.08
- PROK 0.15
- MACD
- NRO 0.02
- PROK -0.01
- Stochastic Oscillator
- NRO 76.00
- PROK 45.45
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.